Histone Deacetylase Inhibitors Interrupt HSP90•RASGRP1 and HSP90•CRAF Interactions to Upregulate BIM and Circumvent Drug Resistance in Lymphoma Cells

Histone deacetylase (HDAC) inhibitors, which are approved for the treatment of cutaneous T cell lymphoma and multiple myeloma, are undergoing evaluation in other lymphoid neoplasms. How they kill susceptible cells is incompletely understood. Here we show that trichostatin A, romidepsin, and panobino...

Descripción completa

Detalles Bibliográficos
Autores principales: Ding, Husheng, Peterson, Kevin L., Correia, Cristina, Koh, Brian, Schneider, Paula A., Nowakowski, Grzegorz S., Kaufmann, Scott H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2016
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5474223/
https://www.ncbi.nlm.nih.gov/pubmed/27890930
http://dx.doi.org/10.1038/leu.2016.357

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5474223/
https://www.ncbi.nlm.nih.gov/pubmed/27890930
http://dx.doi.org/10.1038/leu.2016.357

Ejemplares similares